Antares Pharma, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States. Founded in 1978, the company has established itself as a pioneer in the development of innovative drug delivery systems, particularly in the areas of injectable pharmaceuticals. With a focus on enhancing patient compliance and improving therapeutic outcomes, Antares Pharma offers a range of unique products, including its proprietary auto-injector technology and transdermal delivery systems. The company has achieved significant milestones, including partnerships with major pharmaceutical firms and the successful launch of several key products. Antares Pharma's commitment to innovation and quality has positioned it as a trusted name in the market, making substantial contributions to the fields of endocrinology, pain management, and other therapeutic areas.
How does Antares Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Antares Pharma, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Antares Pharma, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is a current subsidiary of Halozyme Therapeutics, Inc., which may influence its climate commitments and emissions reporting. As of now, Antares Pharma has not established any documented reduction targets or initiatives related to carbon emissions. This lack of specific targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction. However, without specific data or commitments from Antares Pharma, it is challenging to assess their current environmental impact or future plans. Overall, while Antares Pharma is part of a broader industry trend towards climate responsibility, further information is needed to evaluate their specific emissions profile and climate commitments.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Antares Pharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.